Secondly, if ongoing late-phase trials will confirm the positive results from early-phase clinical trials of novel anti-HER2 strategies for HER2-low-positive advanced breast cancer patients (NCT03734029 —Destiny-Breast04 met its primary endpoint—data not presented yet, NCT04494425—Destiny-Breast06), it is expected a rapid transfer of this experimental scenario in the early setting. Here, ERBB2 is linked to breast carcinoma.